Eligibility Criteria

Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
*PARTICIPANTS*
Description

*PARTICIPANTS*

Data type

boolean

Alias
UMLS CUI [1,1]
C3165543
*Inclusion Criteria:*
Description

*Inclusion Criteria:*

Data type

boolean

Alias
UMLS CUI [1,1]
C1512693
Male and female participants were included who met the following criteria:Outpatients or inpatients with nonpsychotic MDD for whom antidepressant treatment is deemed appropriate by the treating clinician.
Description

Male and female participants were included who met the following criteria:Outpatients or inpatients with nonpsychotic MDD for whom antidepressant treatment is deemed appropriate by the treating clinician.

Data type

boolean

Alias
UMLS CUI [1,1]
C0086582
UMLS CUI [1,2]
C0086287
UMLS CUI [1,3]
C0679646
UMLS CUI [1,4]
C1512693
UMLS CUI [1,5]
C0243161
UMLS CUI [1,6]
C0029921
UMLS CUI [1,7]
C0021562
UMLS CUI [1,8]
C1269683
UMLS CUI [1,9]
C1741963
UMLS CUI [1,10]
C1522326
UMLS CUI [1,11]
C0871685
A baseline score of >/= 14 on the HRS-D17.
Description

A baseline score of >/= 14 on the HRS-D17.

Data type

boolean

Alias
UMLS CUI [1,1]
C1442488
UMLS CUI [1,2]
C0449820
UMLS CUI [1,3]
C0451203
Age 18-85 years.
Description

Age 18-85 years.

Data type

boolean

Alias
UMLS CUI [1,1]
C0001779
*Exclusion Criteria:*Subjects with medical contraindications that precluded citalopram or escitalopram treatment and those who previously failed to respond to citalopram or escitalopram were excluded.
Description

*Exclusion Criteria:*Subjects with medical contraindications that precluded citalopram or escitalopram treatment and those who previously failed to respond to citalopram or escitalopram were excluded.

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1099456
UMLS CUI [1,3]
C0008845
UMLS CUI [1,4]
C1553423
UMLS CUI [1,5]
C0231175
UMLS CUI [1,6]
C0087111
UMLS CUI [1,7]
C0681850
UMLS CUI [1,8]
C1301624
Patients with schizophrenia, schizoaffective disorder, or who have Bipolar I disorder were excluded.
Description

Patients with schizophrenia, schizoaffective disorder, or who have Bipolar I disorder were excluded.

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0036341
UMLS CUI [1,3]
C0036337
UMLS CUI [1,4]
C0005586
UMLS CUI [1,5]
C0680251
Subjects who were on antidepressant medication with subtherapeutic results in terms of depression management underwent a medication taper and discontinuation prior to initiation of citalopram or escitalopram treatment. The subjects were closely monitored by the primary physican or psychiatrist during the medication taper and discontinuation phase. The medication taper was determined by the treating physician or psychiatrist. Study subjects who could not be safely tapered from their medication or experienced adverse effects during the taper were excluded from the study.
Description

Subjects who were on antidepressant medication with subtherapeutic results in terms of depression management underwent a medication taper and discontinuation prior to initiation of citalopram or escitalopram treatment. The subjects were closely monitored by the primary physican or psychiatrist during the medication taper and discontinuation phase. The medication taper was determined by the treating physician or psychiatrist. Study subjects who could not be safely tapered from their medication or experienced adverse effects during the taper were excluded from the study.

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0003289
UMLS CUI [1,3]
C1262236
UMLS CUI [1,4]
C1303151
UMLS CUI [1,5]
C0441640
UMLS CUI [1,6]
C0013227
UMLS CUI [1,7]
C0457454
UMLS CUI [1,8]
C0332152
UMLS CUI [1,9]
C1704686
UMLS CUI [1,10]
C1099456
UMLS CUI [1,11]
C0008845
UMLS CUI [1,12]
C1822343
UMLS CUI [1,13]
C1508823
UMLS CUI [1,14]
C0033872
UMLS CUI [1,15]
C0680251
Subjects using the antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis or other diagnoses were not eligible for the study.
Description

Subjects using the antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis or other diagnoses were not eligible for the study.

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0003289
UMLS CUI [1,3]
C0028043
UMLS CUI [1,4]
C0150055
UMLS CUI [1,5]
C1142085
UMLS CUI [1,6]
C1555471
Study subjects who were on antipsychotic medications (e.g., typical and atypical antipsychotic drugs) and mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) were not eligible for the study with the exception of those starting quetiapine after baseline. Trazadone, Melatonin, and Diphenhydramine were allowed for use as rescue medications for insomnia. Benzodiazepines were allowed for treatment of anxiety and atomoxetine for the treatment of attention deficit disorder.
Description

Study subjects who were on antipsychotic medications (e.g., typical and atypical antipsychotic drugs) and mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) were not eligible for the study with the exception of those starting quetiapine after baseline. Trazadone, Melatonin, and Diphenhydramine were allowed for use as rescue medications for insomnia. Benzodiazepines were allowed for treatment of anxiety and atomoxetine for the treatment of attention deficit disorder.

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C2917392
UMLS CUI [1,3]
C1276996
UMLS CUI [1,4]
C1276998
UMLS CUI [1,5]
C0003286
UMLS CUI [1,6]
C0060926
UMLS CUI [1,7]
C0064636
UMLS CUI [1,8]
C0080356
UMLS CUI [1,9]
C0006949
UMLS CUI [1,10]
C0023870
UMLS CUI [1,11]
C1555471
UMLS CUI [1,12]
C0123091
UMLS CUI [1,13]
C1442488
UMLS CUI [2,1]
C0012522
UMLS CUI [2,2]
C0025219
UMLS CUI [2,3]
C0040805
UMLS CUI [2,4]
C0683607
UMLS CUI [2,5]
C5237476
UMLS CUI [2,6]
C0917801
UMLS CUI [3,1]
C0005064
UMLS CUI [3,2]
C0683607
UMLS CUI [3,3]
C0087111
UMLS CUI [3,4]
C0003467
UMLS CUI [4,1]
C0076823
UMLS CUI [4,2]
C0683607
UMLS CUI [4,3]
C0087111
UMLS CUI [4,4]
C0041671
Subjects unable to give informed consent were excluded.
Description

Subjects unable to give informed consent were excluded.

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C1299582
UMLS CUI [1,3]
C0021430
UMLS CUI [1,4]
C0680251
Pregnant subjects were excluded.
Description

Pregnant subjects were excluded.

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0681850
UMLS CUI [1,3]
C0032961

Similar models

Eligibility Criteria

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
*PARTICIPANTS*
Item
*PARTICIPANTS*
boolean
C3165543 (UMLS CUI [1,1])
*Inclusion Criteria:*
Item
*Inclusion Criteria:*
boolean
C1512693 (UMLS CUI [1,1])
Male and female participants were included who met the following criteria:Outpatients or inpatients with nonpsychotic MDD for whom antidepressant treatment is deemed appropriate by the treating clinician.
Item
Male and female participants were included who met the following criteria:Outpatients or inpatients with nonpsychotic MDD for whom antidepressant treatment is deemed appropriate by the treating clinician.
boolean
C0086582 (UMLS CUI [1,1])
C0086287 (UMLS CUI [1,2])
C0679646 (UMLS CUI [1,3])
C1512693 (UMLS CUI [1,4])
C0243161 (UMLS CUI [1,5])
C0029921 (UMLS CUI [1,6])
C0021562 (UMLS CUI [1,7])
C1269683 (UMLS CUI [1,8])
C1741963 (UMLS CUI [1,9])
C1522326 (UMLS CUI [1,10])
C0871685 (UMLS CUI [1,11])
A baseline score of >/= 14 on the HRS-D17.
Item
A baseline score of >/= 14 on the HRS-D17.
boolean
C1442488 (UMLS CUI [1,1])
C0449820 (UMLS CUI [1,2])
C0451203 (UMLS CUI [1,3])
Age 18-85 years.
Item
Age 18-85 years.
boolean
C0001779 (UMLS CUI [1,1])
*Exclusion Criteria:*Subjects with medical contraindications that precluded citalopram or escitalopram treatment and those who previously failed to respond to citalopram or escitalopram were excluded.
Item
*Exclusion Criteria:*Subjects with medical contraindications that precluded citalopram or escitalopram treatment and those who previously failed to respond to citalopram or escitalopram were excluded.
boolean
C0680251 (UMLS CUI [1,1])
C1099456 (UMLS CUI [1,2])
C0008845 (UMLS CUI [1,3])
C1553423 (UMLS CUI [1,4])
C0231175 (UMLS CUI [1,5])
C0087111 (UMLS CUI [1,6])
C0681850 (UMLS CUI [1,7])
C1301624 (UMLS CUI [1,8])
Patients with schizophrenia, schizoaffective disorder, or who have Bipolar I disorder were excluded.
Item
Patients with schizophrenia, schizoaffective disorder, or who have Bipolar I disorder were excluded.
boolean
C0030705 (UMLS CUI [1,1])
C0036341 (UMLS CUI [1,2])
C0036337 (UMLS CUI [1,3])
C0005586 (UMLS CUI [1,4])
C0680251 (UMLS CUI [1,5])
Subjects who were on antidepressant medication with subtherapeutic results in terms of depression management underwent a medication taper and discontinuation prior to initiation of citalopram or escitalopram treatment. The subjects were closely monitored by the primary physican or psychiatrist during the medication taper and discontinuation phase. The medication taper was determined by the treating physician or psychiatrist. Study subjects who could not be safely tapered from their medication or experienced adverse effects during the taper were excluded from the study.
Item
Subjects who were on antidepressant medication with subtherapeutic results in terms of depression management underwent a medication taper and discontinuation prior to initiation of citalopram or escitalopram treatment. The subjects were closely monitored by the primary physican or psychiatrist during the medication taper and discontinuation phase. The medication taper was determined by the treating physician or psychiatrist. Study subjects who could not be safely tapered from their medication or experienced adverse effects during the taper were excluded from the study.
boolean
C0681850 (UMLS CUI [1,1])
C0003289 (UMLS CUI [1,2])
C1262236 (UMLS CUI [1,3])
C1303151 (UMLS CUI [1,4])
C0441640 (UMLS CUI [1,5])
C0013227 (UMLS CUI [1,6])
C0457454 (UMLS CUI [1,7])
C0332152 (UMLS CUI [1,8])
C1704686 (UMLS CUI [1,9])
C1099456 (UMLS CUI [1,10])
C0008845 (UMLS CUI [1,11])
C1822343 (UMLS CUI [1,12])
C1508823 (UMLS CUI [1,13])
C0033872 (UMLS CUI [1,14])
C0680251 (UMLS CUI [1,15])
Subjects using the antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis or other diagnoses were not eligible for the study.
Item
Subjects using the antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis or other diagnoses were not eligible for the study.
boolean
C0681850 (UMLS CUI [1,1])
C0003289 (UMLS CUI [1,2])
C0028043 (UMLS CUI [1,3])
C0150055 (UMLS CUI [1,4])
C1142085 (UMLS CUI [1,5])
C1555471 (UMLS CUI [1,6])
Study subjects who were on antipsychotic medications (e.g., typical and atypical antipsychotic drugs) and mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) were not eligible for the study with the exception of those starting quetiapine after baseline. Trazadone, Melatonin, and Diphenhydramine were allowed for use as rescue medications for insomnia. Benzodiazepines were allowed for treatment of anxiety and atomoxetine for the treatment of attention deficit disorder.
Item
Study subjects who were on antipsychotic medications (e.g., typical and atypical antipsychotic drugs) and mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) were not eligible for the study with the exception of those starting quetiapine after baseline. Trazadone, Melatonin, and Diphenhydramine were allowed for use as rescue medications for insomnia. Benzodiazepines were allowed for treatment of anxiety and atomoxetine for the treatment of attention deficit disorder.
boolean
C0681850 (UMLS CUI [1,1])
C2917392 (UMLS CUI [1,2])
C1276996 (UMLS CUI [1,3])
C1276998 (UMLS CUI [1,4])
C0003286 (UMLS CUI [1,5])
C0060926 (UMLS CUI [1,6])
C0064636 (UMLS CUI [1,7])
C0080356 (UMLS CUI [1,8])
C0006949 (UMLS CUI [1,9])
C0023870 (UMLS CUI [1,10])
C1555471 (UMLS CUI [1,11])
C0123091 (UMLS CUI [1,12])
C1442488 (UMLS CUI [1,13])
C0012522 (UMLS CUI [2,1])
C0025219 (UMLS CUI [2,2])
C0040805 (UMLS CUI [2,3])
C0683607 (UMLS CUI [2,4])
C5237476 (UMLS CUI [2,5])
C0917801 (UMLS CUI [2,6])
C0005064 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C0003467 (UMLS CUI [3,4])
C0076823 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
C0087111 (UMLS CUI [4,3])
C0041671 (UMLS CUI [4,4])
Subjects unable to give informed consent were excluded.
Item
Subjects unable to give informed consent were excluded.
boolean
C0681850 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0680251 (UMLS CUI [1,4])
Pregnant subjects were excluded.
Item
Pregnant subjects were excluded.
boolean
C0680251 (UMLS CUI [1,1])
C0681850 (UMLS CUI [1,2])
C0032961 (UMLS CUI [1,3])